文献速递结核与非结核分枝杆菌

用于评估体内结核免疫的人型卡介苗攻毒模型的1期开放标签剂量递增试验

Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
PubMed 文献 · J Infect Dis · 2024-01-01

这项1期开放标签剂量递增试验中,92名健康成人接受单次皮内注射2×10^6至16×10^6 CFU的卡介苗(BCG)。剂量至8×10^6安全,并观察到随剂量递增BCG排出增加;MGIT时间至阳性是较一致且精确的排出指标,功效分析提示小队列(n=30)可检测MGIT时间至阳性(曲线下面积)10%的差异。安全性、反应原性和免疫原性特征表明该BCG人体攻毒模型可行,可促进疫苗研发。

要点

  • 92名健康成人单次皮内接种2×10^6至16×10^6 CFU卡介苗,剂量至8×10^6安全。
  • 随剂量递增可见BCG排出增加,MGIT时间至阳性为较一致且精确的排出指标。
  • 安全性、反应原性和免疫原性特征表明该BCG人体攻毒模型可行。

核心结论

  • 安全性、反应原性和免疫原性特征表明该BCG人体攻毒模型可行,可用于评估体内结核免疫,并可能促进疫苗研发过程。

研究设计与样本

  • 1期开放标签剂量递增试验,92名健康成人接受单次皮内注射2×10^6至16×10^6 CFU的卡介苗(BCG)。
  • 主要终点为安全性和通过定量聚合酶链反应、菌落形成单位平板接种和MGIT BACTEC培养测定的BCG排出。

主要发现

  • 剂量至8×10^6安全,并有证据表明随剂量递增BCG排出增加。
  • MGIT时间至阳性测定是较一致且精确的排出指标。
  • 功效分析提示小队列(n=30)可检测MGIT时间至阳性(曲线下面积)10%的差异。
  • 鉴定出与排出相关的分枝杆菌免疫潜在生物标志物。
  • 转录组分析揭示BCG攻毒的剂量和时间依赖性效应,并鉴定出一个推定的转录性结核保护特征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A controlled human infection model for assessing tuberculosis (TB) immunity can accelerate new vaccine development. METHODS: In this phase 1 dose escalation trial, 92 healthy adults received a single intradermal injection of 2 × 106 to 16 × 106 colony-forming units of Bacillus Calmette-Guérin (BCG). The primary endpoints were safety and BCG shedding as measured by quantitative polymerase chain reaction, colony-forming unit plating, and MGIT BACTEC culture. RESULTS: Doses up to 8 × 106 were safe, and there was evidence for increased BCG shedding with dose escalation. The MGIT time-to-positivity assay was the most consistent and precise measure of shedding. Power analyses indicated that 10% differences in MGIT time to positivity (area under the curve) could be detected in small cohorts (n = 30). Potential biomarkers of mycobacterial immunity were identified that correlated with shedding. Transcriptomic analysis uncovered dose- and time-dependent effects of BCG challenge and identified a putative transcriptional TB protective signature. Furthermore, we identified immunologic and transcriptomal differences that could represent an immune component underlying the observed higher rate of TB disease incidence in males. CONCLUSIONS: The safety, reactogenicity, and immunogenicity profiles indicate that this BCG human challenge model is feasible for assessing in vivo TB immunity and could facilitate the vaccine development process. CLINICAL TRIALS REGISTRATION: NCT01868464 (ClinicalTrials.gov).

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Blazevic A, Edwards RL, Xia M, et al. Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo. J Infect Dis. 2024. PMID: 38019956. doi:10.1093/infdis/jiad441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。